Early phase development of PI3kinase inhibitors for anticancer therapies
PI3KCA-specific inhibitors represent a new class of promising drugs in the treatment of tumors with the mutated P110α subunit. However, despite the proven improvement in clinical outcomes, the management of patients in terms of efficacy and toxicity remains the main challenge. To maximize efficacy and safety, molecular stratification of patients by genomic profiling and the development of targeted combinations are crucial to optimizing benefits.
Authors
- Evžen Amler
- Rossella Sperlongano
- Miryam Del Vicario (ORCID: https://orcid.org/0000-0002-9888-8364)
- Angela Lombardi (ORCID: https://orcid.org/0000-0001-5421-9970)
- Federica Melisi (ORCID: https://orcid.org/0000-0002-5957-9876)
- Carlo Caputo (ORCID: https://orcid.org/0000-0001-5603-4881)
- Alois Nečas
- Michele Caraglia (ORCID: https://orcid.org/0000-0003-2408-6091)
- Anna Grimaldi (ORCID: https://orcid.org/0000-0002-3957-9780)
- Raffaele Addeo (ORCID: https://orcid.org/0000-0001-9197-8060)
- Domenico Cautela
Institutions
- University of Veterinary Sciences Brno (CZ)
- Università degli Studi eCampus (IT)
- Genetic Information Research Institute (US)
- University of Campania "Luigi Vanvitelli" (IT)
- Charles University (CZ)
- Nuovo Ospedale San Giovanni di Dio (IT)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1080/13543784.2025.2582080
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81